Scalzulli PR - Search Results

1

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Musso M, et al. Among authors: scalzulli pr. Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26458240 Free PMC article.

2

Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.

Musto P, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Modoni S, Parlatore L, Valvano MR, Carotenuto M. Musto P, et al. Br J Haematol. 1995 May;90(1):125-30. doi: 10.1111/j.1365-2141.1995.tb03390.x. Br J Haematol. 1995. PMID: 7786774

3

Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.

Sajeva MR, Greco MM, Cascavilla N, D'Arena G, Scalzulli P, Melillo L, Minervini MM, Bonini A, Di Mauro L, Carotenuto M, Musto P. Sajeva MR, et al. Bone Marrow Transplant. 1996 Jul;18(1):225-7. Bone Marrow Transplant. 1996. PMID: 8832022

4

Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis.

Musto P, Falcone A, D'Arena G, Scalzulli PR, Matera R, Minervini MM, Lombardi GF, Modoni S, Longo A, Carotenuto M. Musto P, et al. Among authors: scalzulli pr. Eur J Haematol. 1997 May;58(5):314-9. doi: 10.1111/j.1600-0609.1997.tb01677.x. Eur J Haematol. 1997. PMID: 9222286 Clinical Trial.

5

Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies.

D'Arena G, Musto P, Di Mauro L, Cascavilla N, Iacono ND, Scalzulli PR, Matera R, Carotenuto M. D'Arena G, et al. Among authors: scalzulli pr. Am J Hematol. 1998 Aug;58(4):255-62. doi: 10.1002/(sici)1096-8652(199808)58:4<255::aid-ajh1>3.0.co;2-p. Am J Hematol. 1998. PMID: 9692386 Free article.

6

Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.

Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M. Musto P, et al. Among authors: scalzulli pr. Haematologica. 2001 Jan;86(1):44-51. Haematologica. 2001. PMID: 11146570

7

Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.

Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, Scalzulli PR, Dell'Olio M, La Sala A, Mantuano S, Nobile M, Carella AM. Musto P, et al. Among authors: scalzulli pr. Leuk Lymphoma. 2003 Sep;44(9):1545-8. doi: 10.3109/10428190309178778. Leuk Lymphoma. 2003. PMID: 14565658 Clinical Trial.

8

Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.

Musto P, Falcone A, Sanpaolo G, Bodenizza C, Perla G, Minervini MM, Cascavilla N, Dell'Olio M, La Sala A, Mantuano S, Melillo L, Nobile M, Scalzulli PR, Bisceglia M, Carella AM. Musto P, et al. Among authors: scalzulli pr. Leuk Lymphoma. 2004 Jun;45(6):1219-22. doi: 10.1080/10428190310001641143. Leuk Lymphoma. 2004. PMID: 15360005

9

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.

Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM. Musto P, et al. Among authors: scalzulli pr. Br J Haematol. 2005 Jan;128(2):204-9. doi: 10.1111/j.1365-2141.2004.05288.x. Br J Haematol. 2005. PMID: 15638854 Free article.

10

Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer.

Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P, Gonella R, Ballestrero A, Patrone F. Carella AM, et al. Lancet. 2005 Jul 23-29;366(9482):318-20. doi: 10.1016/S0140-6736(05)66989-9. Lancet. 2005. PMID: 16039336 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters